Tetrahydroquinoline derivatives as cannabinoid receptor modulators

US7884113B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Chongqing Sun · Plainsboro, US
• Doree F. Sitkoff · Dresher, US
• William R. Ewing · Yardley, US
• Yanting Huang · Pennington, US
• Bruce A. Ellsworth · Princeton, US
• Richard B. Sulsky · Somerville, US
• Annapurna Pendri · South Glastonbury, US
• Samuel Gerritz · Guilford, US
• Natesan Murugesan · Lawrenceville, US
• Zhengxiang Gu · Princeton, US

Key dates

• Filing date: Apr 24, 2008
• Grant date: Feb 8, 2011
• Expiry date: Jul 7, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention provides for compounds of formula I Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.